Cardiac tissue engineering using human stem cell-derived cardiomyocytes for disease modeling and drug discovery

Irene C. Turnbull, Deborah Lieu, Ronald A. Li, Kevin D. Costa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Cardiovascular disease (CVD) is the most prevalent health problem in the world, and the high mortality rate associated with irreversibly injured heart muscle motivates an urgent need for the development of novel therapies to treat damaged myocardium. Recently, human engineered cardiac tissues (hECT) have been created using cardiomyocytes (CM) derived from human embryonic stem cells (hESC) and human induced pluripotent stem cells (hiPSC). Although a healthy adult phenotype remains elusive, such hECT display structural and functional properties that recapitulate key aspects of natural human myocardium, including dose related responses to compounds with known chronotropic, inotropic and arrhythmogenic effects. Thus, hECT offer the advantage over traditional in vitro culture models of providing a biomimetic 3D environment for the study of myocardial physiopathology, and may be used to generate preclinical models for the development and screening of therapies for CVD.

Original languageEnglish (US)
JournalDrug Discovery Today: Disease Models
Volume9
Issue number4
DOIs
StatePublished - Dec 2012

Fingerprint

Drug Discovery
Tissue Engineering
Cardiac Myocytes
Stem Cells
Myocardium
Cardiovascular Diseases
Induced Pluripotent Stem Cells
Biomimetics
Phenotype
Mortality
Health
Therapeutics

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine

Cite this

Cardiac tissue engineering using human stem cell-derived cardiomyocytes for disease modeling and drug discovery. / Turnbull, Irene C.; Lieu, Deborah; Li, Ronald A.; Costa, Kevin D.

In: Drug Discovery Today: Disease Models, Vol. 9, No. 4, 12.2012.

Research output: Contribution to journalArticle

@article{90614e95459c491cb31aa8325e8f1387,
title = "Cardiac tissue engineering using human stem cell-derived cardiomyocytes for disease modeling and drug discovery",
abstract = "Cardiovascular disease (CVD) is the most prevalent health problem in the world, and the high mortality rate associated with irreversibly injured heart muscle motivates an urgent need for the development of novel therapies to treat damaged myocardium. Recently, human engineered cardiac tissues (hECT) have been created using cardiomyocytes (CM) derived from human embryonic stem cells (hESC) and human induced pluripotent stem cells (hiPSC). Although a healthy adult phenotype remains elusive, such hECT display structural and functional properties that recapitulate key aspects of natural human myocardium, including dose related responses to compounds with known chronotropic, inotropic and arrhythmogenic effects. Thus, hECT offer the advantage over traditional in vitro culture models of providing a biomimetic 3D environment for the study of myocardial physiopathology, and may be used to generate preclinical models for the development and screening of therapies for CVD.",
author = "Turnbull, {Irene C.} and Deborah Lieu and Li, {Ronald A.} and Costa, {Kevin D.}",
year = "2012",
month = "12",
doi = "10.1016/j.ddmod.2012.11.001",
language = "English (US)",
volume = "9",
journal = "Drug Discovery Today: Disease Models",
issn = "1740-6757",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Cardiac tissue engineering using human stem cell-derived cardiomyocytes for disease modeling and drug discovery

AU - Turnbull, Irene C.

AU - Lieu, Deborah

AU - Li, Ronald A.

AU - Costa, Kevin D.

PY - 2012/12

Y1 - 2012/12

N2 - Cardiovascular disease (CVD) is the most prevalent health problem in the world, and the high mortality rate associated with irreversibly injured heart muscle motivates an urgent need for the development of novel therapies to treat damaged myocardium. Recently, human engineered cardiac tissues (hECT) have been created using cardiomyocytes (CM) derived from human embryonic stem cells (hESC) and human induced pluripotent stem cells (hiPSC). Although a healthy adult phenotype remains elusive, such hECT display structural and functional properties that recapitulate key aspects of natural human myocardium, including dose related responses to compounds with known chronotropic, inotropic and arrhythmogenic effects. Thus, hECT offer the advantage over traditional in vitro culture models of providing a biomimetic 3D environment for the study of myocardial physiopathology, and may be used to generate preclinical models for the development and screening of therapies for CVD.

AB - Cardiovascular disease (CVD) is the most prevalent health problem in the world, and the high mortality rate associated with irreversibly injured heart muscle motivates an urgent need for the development of novel therapies to treat damaged myocardium. Recently, human engineered cardiac tissues (hECT) have been created using cardiomyocytes (CM) derived from human embryonic stem cells (hESC) and human induced pluripotent stem cells (hiPSC). Although a healthy adult phenotype remains elusive, such hECT display structural and functional properties that recapitulate key aspects of natural human myocardium, including dose related responses to compounds with known chronotropic, inotropic and arrhythmogenic effects. Thus, hECT offer the advantage over traditional in vitro culture models of providing a biomimetic 3D environment for the study of myocardial physiopathology, and may be used to generate preclinical models for the development and screening of therapies for CVD.

UR - http://www.scopus.com/inward/record.url?scp=84876675545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876675545&partnerID=8YFLogxK

U2 - 10.1016/j.ddmod.2012.11.001

DO - 10.1016/j.ddmod.2012.11.001

M3 - Article

AN - SCOPUS:84876675545

VL - 9

JO - Drug Discovery Today: Disease Models

JF - Drug Discovery Today: Disease Models

SN - 1740-6757

IS - 4

ER -